TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25543678

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibrates, budesonide, and obeticholic acid
Number of subjects: 0
Study: 25544158

Group type: EXPERIMENTAL
Intervention: Preoperative FA values in PAD patients (mean ± SD 0.370 ± 0.017)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy age matched participants (15 participants)
Number of subjects: 24
Study: 25544296

Group type: EXPERIMENTAL
Intervention: Asymptomatic third molars with probing depths <4 mm at enrollment
Number of subjects: 129
Study: 25545105

Group type: EXPERIMENTAL
Intervention: FAmily CEntered Advance Care Planning (ACP) for Teens with Cancer (FACE-TC) study
Number of subjects: 17

Group type: COMPARATOR
Intervention: Post-hoc survey sent to oncology providers
Number of subjects: 17
Study: 25545153

Group type: EXPERIMENTAL
Intervention: G-CSF priming, clofarabine (30 mg m(-2) day(-1) × 5), and cytarabine (2 g m(-2) day(-1) × 5)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G-CSF priming, clofarabine, and cytarabine
Number of subjects: 50
Study: 25545244

Group type: EXPERIMENTAL
Intervention: peg-proline-IFNα-2b
Number of subjects: 51
Study: 25545465

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 354
Study: 25546176

Group type: EXPERIMENTAL
Intervention: Pre-bolus low-dose contrast injection (1.3 mL and 0.05 mmol/kg of gadobenate dimeglumine)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pre-bolus acquisition
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pre-bolus and main bolus acquisitions
Number of subjects: 21
Study: 25546395

Group type: EXPERIMENTAL
Intervention: HLA-DRB1454
Number of subjects: 0
Study: 25547133

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC)
Number of subjects: 81
Study: 25547338

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) and room service system care
Number of subjects: 70

Group type: COMPARATOR
Intervention: Preoperative nutrition risk
Number of subjects: 70
Study: 25547501

Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (SCT) with a sibling donor
Number of subjects: 304

Group type: COMPARATOR
Intervention: No donor, received consolidation or autologous SCT
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Allogeneic SCT with a sibling donor in patients with normal karyotype and no FLT3 internal tandem duplication
Number of subjects: 304

Group type: COMPARATOR
Intervention: No donor in patients with normal karyotype and no FLT3 internal tandem duplication
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Allogeneic SCT with a sibling donor
Number of subjects: 304

Group type: COMPARATOR
Intervention: No donor
Number of subjects: 304
Study: 25548919

Group type: EXPERIMENTAL
Intervention: Functional near-infrared spectroscopy (fNIRS) combined with muscle and kinematic monitoring during motor tasks.
Number of subjects: 0
Study: 25548978

Group type: EXPERIMENTAL
Intervention: Baseline serum total testosterone (TT) and free testosterone (FT) levels
Number of subjects: 788
Study: 25549051

Group type: EXPERIMENTAL
Intervention: Multiparous mothers
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Primiparous mothers
Number of subjects: 1099
Study: 25549988

Group type: EXPERIMENTAL
Intervention: Healthy AMA women (age > 35 yr)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy non-AMA women (age ≤ 35 yr)
Number of subjects: 0
Study: 25550361

Group type: EXPERIMENTAL
Intervention: Mutations in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 in s-AML patients
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: s-AML genetic subtype
Number of subjects: 299
Study: 25552401

Group type: EXPERIMENTAL
Intervention: 250 mg/day gefitinib and 400 mg/day vorinostat
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 250 mg/day gefitinib and 400 mg/day vorinostat in EGFR-mutant NSCLC
Number of subjects: 52
Study: 25552483

Group type: EXPERIMENTAL
Intervention: L19-IL2 combined with radiotherapy
Number of subjects: 0
Study: 25552564

Group type: EXPERIMENTAL
Intervention: High-BMI group
Number of subjects: 780

Group type: COMPARATOR
Intervention: Low-BMI group
Number of subjects: 780
Study: 25553059

Group type: EXPERIMENTAL
Intervention: Standard diet (33% fat, 52% carbohydrate, 15% protein) for 7 days followed by a test meal (40% fat, 40% carbohydrate, 20% protein) on Day 8.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity index (SI) calculated from the minimal model.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) measurement.
Number of subjects: 32
Study: 25553245

Group type: EXPERIMENTAL
Intervention: Sepsis patients
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Severe sepsis and septic shock patients
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sepsis patients 48 hours before death
Number of subjects: 65

Group type: COMPARATOR
Intervention: Metabolic profiling
Number of subjects: 65
Study: 25554012

Group type: EXPERIMENTAL
Intervention: PARP inhibition
Number of subjects: 0
Study: 25554484

Group type: EXPERIMENTAL
Intervention: Community-based interventions (not specified in detail)
Number of subjects: 1118
Study: 25555214

Group type: EXPERIMENTAL
Intervention: Moderate weight gain (~6%) in MNO subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate weight gain (~6%) in MAO subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Biological pathways and genes associated with adipose tissue lipogenesis in MNO subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Biological pathways and genes associated with adipose tissue lipogenesis in MAO subjects
Number of subjects: 20
Study: 25555267

Group type: EXPERIMENTAL
Intervention: Abnormal cIMT (>0.90 mm)
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Age class 65-74 yrs.
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Age class ≥75 yrs.
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Calcium-channel blockers use
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Persistent/permanent NVAF
Number of subjects: 673
Study: 25555354

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg/day) for 7 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EPA+DHA (2.6g/day) for 28 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both aspirin and EPA+DHA for another 7 days
Number of subjects: 30
Study: 25555420

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg orally once daily for 28-day cycles until disease progression or limiting toxicities
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 51
Study: 25555530

Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 120
Study: 25556540

Group type: EXPERIMENTAL
Intervention: Increased plasma concentration of apolipoprotein H (apoH)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Apolipoprotein H (apoH)
Number of subjects: 189
Study: 25556716

Group type: EXPERIMENTAL
Intervention: IGN523 (anti-CD98 antibody)
Number of subjects: 0
Study: 25556837

Group type: EXPERIMENTAL
Intervention: Methadone maintenance dose
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Fractioned methadone intake
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Bodyweight
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: History of cocaine dependence
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ethnicity
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Liver/intestinal CYP3A4 activity
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Concomitant CYP3A4 inhibitors
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms
Number of subjects: 81
Study: 25557329

Group type: EXPERIMENTAL
Intervention: Multimodal analgesic regimen (gabapentin, ketorolac, dexamethasone, acetaminophen, ibuprofen)
Number of subjects: 48
Study: 25557584

Group type: EXPERIMENTAL
Intervention: Irish set dancing
Number of subjects: 10
Study: 25557634

Group type: COMPARATOR
Intervention: Overweight/obese adults
Number of subjects: 527

Group type: COMPARATOR
Intervention: Overweight/obese juveniles
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Overweight/obese juveniles and adults
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Juveniles with low vitD-status
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Juveniles and adults
Number of subjects: 527
Study: 25558798

Group type: EXPERIMENTAL
Intervention: MusiQoL index score at 24 months
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Baseline EDSS score
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: At least one relapse during follow-up
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Occupational status and marital status
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Sociodemographics (age, marital status, occupational status) and baseline QoL scores
Number of subjects: 526
Study: 25558980

Group type: EXPERIMENTAL
Intervention: Intraoperative dose of morphine
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: FAAH SNP, rs324420
Number of subjects: 259
Study: 25559048

Group type: EXPERIMENTAL
Intervention: Cervicovaginal lavage (CVL) with sterile saline and peripheral blood sample
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: GM-CSF levels in symptomatic women
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: GM-CSF levels in asymptomatic women
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Postmenopausal vulvovaginal symptoms
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Serum or CVL cytokines
Number of subjects: 34
Study: 25559400

Group type: EXPERIMENTAL
Intervention: Increased fasting plasma glucose (FPG) levels during weight gain
Number of subjects: 144

Group type: COMPARATOR
Intervention: Insulin infusion
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Higher baseline fasting plasma glucose (FPG)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Weight gain
Number of subjects: 144
Study: 25559651

Group type: EXPERIMENTAL
Intervention: 2D speckle-tracking echocardiography and cardiac magnetic resonance imaging (CMR)
Number of subjects: 95
Study: 25560174

Group type: EXPERIMENTAL
Intervention: Dalfampridine-ER 5 mg
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Dalfampridine-ER 10 mg
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study: 25560203

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia using 0.375% or 0.5% ropivacaine 15 mL, followed by continuous infusion of 0.15% ropivacaine 2 mL·hr(-1) with fentanyl 8 μg·hr(-1) postoperatively
Number of subjects: 439
Study: 25560712

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy stopped after negative D-dimer test results
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy stopped after negative D-dimer test results in men
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy stopped after negative D-dimer test results in women not associated with estrogen therapy
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy stopped after negative D-dimer test results in women associated with estrogen therapy
Number of subjects: 410
Study: 25560819

Group type: EXPERIMENTAL
Intervention: External facilitation (EF) - a one-year multifaceted intervention including support, guidance, practice audits, and feedback.
Number of subjects: 101

Group type: COMPARATOR
Intervention: Educational outreach visits (EOVs) - one session of three hours of lectures about the guidelines.
Number of subjects: 101
Study: 25562355

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 2038
Study: 25563429

Group type: EXPERIMENTAL
Intervention: Lestaurtinib 140 mg twice daily (maximum tolerated dose)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lestaurtinib (doses lower than 140 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lestaurtinib
Number of subjects: 34
Study: 25563640

Group type: EXPERIMENTAL
Intervention: Intraplaque hemorrhage (IPH)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Thin/ruptured fibrous cap (TRFC)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: MRI detection of infarcts
Number of subjects: 101
Study: 25564232

Group type: EXPERIMENTAL
Intervention: Healthy individuals
Number of subjects: 17

Group type: COMPARATOR
Intervention: Temporal lobe epilepsy (TLE) patients
Number of subjects: 17
Study: 25564282

Group type: EXPERIMENTAL
Intervention: Graphic warnings applied to the front and back of smokers' cigarette packs
Number of subjects: 76
Study: 25564781

Group type: EXPERIMENTAL
Intervention: Single-lumen endotracheal tube (SLT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Double-lumen endotracheal tube (DLT)
Number of subjects: 44
Study: 25564820

Group type: EXPERIMENTAL
Intervention: Bilirubin conjugates (Bc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duration of cholestasis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum albumin levels
Number of subjects: 0
Study: 25564897

Group type: EXPERIMENTAL
Intervention: Adjuvant paclitaxel and trastuzumab
Number of subjects: 406
Study: 25565363

Group type: EXPERIMENTAL
Intervention: Presence of at least one additional chronic comorbidity
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Number of pack years
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: FEV1
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Presence of at least one additional comorbidity
Number of subjects: 228
Study: 25565457

Group type: EXPERIMENTAL
Intervention: Chest compression rates between 100 and 120 compressions/min
Number of subjects: 10371

Group type: COMPARATOR
Intervention: Compression rates <80, 80-99, 120-139, ≥140 compressions/min
Number of subjects: 10371

Group type: COMPARATOR
Intervention: Reference group (100-119 compressions/min)
Number of subjects: 10371
Study: 25565635

Group type: EXPERIMENTAL
Intervention: Myoblast preparations with genomic abnormalities
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prolonged cultures of myoblasts
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Myoblasts in soft agar or in vivo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Molecular analysis of individual p53 transcripts
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CGH array and exome sequencing
Number of subjects: 10
Study: 25565885

Group type: COMPARATOR
Intervention: Pregabalin 300 mg/d
Number of subjects: 1233
Study: 25566367

Group type: EXPERIMENTAL
Intervention: Culturally specific group cognitive behavioral therapy (CS-CBT)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Standard group cognitive behavioral therapy (control)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Both groups receive transdermal nicotine patch (TNP) for 8 weeks
Number of subjects: 247
Study: 25566369

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) and Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 0
Study: 25566379

Group type: EXPERIMENTAL
Intervention: Dialogue-based psychosocial nursing intervention in primary care (individual or group encounters)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Qualitative interviews focusing on participant experiences
Number of subjects: 25
Study: 25566383

Group type: EXPERIMENTAL
Intervention: Culturally tailored smoking cessation program
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard smoking cessation program (Courage to Quit)
Number of subjects: 400
Study: 25566387

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR) + D-cycloserine (DCS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cognitive Remediation (CR) + placebo
Number of subjects: 40
Study: 25566391

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (16 sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term dynamic psychotherapy (16 sessions)
Number of subjects: 0
Study: 25566392

Group type: EXPERIMENTAL
Intervention: Pure Procrastination Scale
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Irrational Procrastination Scale
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Susceptibility to Temptation Scale
Number of subjects: 710
Study: 25566998

Group type: EXPERIMENTAL
Intervention: Scale for the Assessment and Rating of Ataxia (SARA)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Inventory of Non-Ataxia Signs (INAS)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Spinocerebellar Ataxia Functional Index (SCAFI)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Neurocognitive phonemic verbal fluency test
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Activities of daily living (ADL) part of the Friedreich's Ataxia Rating Scale
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: EQ-5D (health-related quality of life)
Number of subjects: 592
Study: 25567235

Group type: EXPERIMENTAL
Intervention: Locally relevant functioning assessment instrument (FAI)
Number of subjects: 142

Group type: COMPARATOR
Intervention: World Health Organization's Disability Assessment Schedule (WHODAS) 12-item version
Number of subjects: 142
Study: 25567425

Group type: EXPERIMENTAL
Intervention: Antipsychotic medications (olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Antipsychotic treatment (after 6 months)
Number of subjects: 520
Study: 25567501

Group type: EXPERIMENTAL
Intervention: MMA pregnancies (isolated MMA)
Number of subjects: 17
Study: 25568297

Group type: EXPERIMENTAL
Intervention: Triheptanoin for 1 month
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 10
Study: 25568299

Group type: EXPERIMENTAL
Intervention: Dystroglycanopathy cohort
Number of subjects: 30
Study: 25568347

Group type: EXPERIMENTAL
Intervention: R-MPV chemotherapy (rituximab, methotrexate 3.5 g/m(2), procarbazine, vincristine)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HDC with thiotepa, cyclophosphamide, and busulfan followed by ASCT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 32
Study: 25572023

Group type: EXPERIMENTAL
Intervention: TAXUS Element stent
Number of subjects: 1014
Study: 25572091

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT with 70%-90% SUVmax thresholds
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT with 30%-60% SUVmax thresholds
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT during radiotherapy
Number of subjects: 39
Study: 25572193

Group type: EXPERIMENTAL
Intervention: Urine AQP1 concentrations in RCC patients (n=47)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Urine PLIN2 concentrations in RCC patients (n=47)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Urine AQP1 concentrations in bladder cancer patients (n=22)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Urine PLIN2 concentrations in bladder cancer patients (n=22)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Urine AQP1 concentrations in prostate cancer patients (n=27)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Urine PLIN2 concentrations in prostate cancer patients (n=27)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Urine AQP1 concentrations in chromophobe tumors (n=7)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Urine PLIN2 concentrations in chromophobe tumors (n=7)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Urine AQP1 concentrations in benign renal oncocytomas (n=9)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Urine PLIN2 concentrations in benign renal oncocytomas (n=9)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Urine AQP1 concentrations in angiomyolipomas (n=7)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Urine PLIN2 concentrations in angiomyolipomas (n=7)
Number of subjects: 105
Study: 25572329

Group type: EXPERIMENTAL
Intervention: Panobinostat 30 mg 3 times per week, every other week, in combination with bevacizumab 10 mg/kg every other week
Number of subjects: 39
Study: 25572505

Group type: EXPERIMENTAL
Intervention: Major HAIs (pneumonia, sepsis, Clostridium difficile colitis)
Number of subjects: 4320

Group type: EXPERIMENTAL
Intervention: Major HAIs
Number of subjects: 4320

Group type: EXPERIMENTAL
Intervention: Readmissions due to major HAIs
Number of subjects: 4320
Study: 25572507

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 5800
Study: 25572917

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.6 mg/m² intravenously once-weekly for six cycles with dexamethasone 40 mg on the day of and day after bortezomib
Number of subjects: 50
Study: 25573455

Group type: EXPERIMENTAL
Intervention: Long-term electrocardiography (ECG) Holter monitoring
Number of subjects: 98
Study: 25573884

Group type: EXPERIMENTAL
Intervention: Increased glycemic variability (assessed by MAGE) in women
Number of subjects: 87

Group type: COMPARATOR
Intervention: Cardiac autonomic modulation measures in men
Number of subjects: 87
Study: 25573987

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with rituximab
Number of subjects: 49
Study: 25574042

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel daily disposable lenses (SiHyDD)
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Hydrogel daily disposable lenses (HydDD)
Number of subjects: 1171
Study: 25574088

Group type: EXPERIMENTAL
Intervention: TNBS treatment in rats
Number of subjects: 12

Group type: COMPARATOR
Intervention: IBS patients
Number of subjects: 12
Study: 25574704

Group type: EXPERIMENTAL
Intervention: Maternal estimated insulin resistance in the first half of pregnancy
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Maternal glucose levels in the second half of pregnancy
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein in the first half of pregnancy
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Free fatty acid levels in the second half of pregnancy
Number of subjects: 804
Study: 25575503

Group type: EXPERIMENTAL
Intervention: Parental presence during physician consultations
Number of subjects: 0

Group type: COMPARATOR
Intervention: No parental presence during physician consultations
Number of subjects: 0
Study: 25575538

Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone (Pom-Dex)
Number of subjects: 50
Study: 25576273

Group type: EXPERIMENTAL
Intervention: OMEGA stent (bare platinum chromium element stent)
Number of subjects: 328